Condition
Relapsed Myelodysplastic Syndromes
Total Trials
3
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Active Not Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06846606Phase 1Active Not Recruiting
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT04891757Phase 1Active Not Recruiting
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
NCT03091933Phase 1Unknown
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
Showing all 3 trials